Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rehabilitacion (Madr) ; 56(2): 99-107, 2022.
Artigo em Espanhol | MEDLINE | ID: mdl-33814157

RESUMO

INTRODUCTION AND OBJECTIVES: Cardiac rehabilitation has the highest level of recognition in medical guideline references, however there are still little-explored training modalities. We study the effects of an interdisciplinary program after acute coronary syndrome (ACS) in phase II secondary prevention. METHODS: Between January 2008 and December 2018, 439 patients with stable ischemic heart disease and preserved systolic function were included, as maximum 2 month after the ACS. A combined aerobic resistance training program in a variable continuous method and muscle toning with overload and/or ballast was applied, in addition to nutritional counseling and psychological-educational therapy for 12 weeks. RESULTS: 378 patients finished. The functional capacity increases in the incremental stress test (1.76 METS; CI 95%: 1.59-1.96, p < 0.001) and in the six minutes walking test (32.58 m; CI 95%: 29.24-35.92, p < 0.001). Leisure physical activity in IPAQ increased (763.27 min/week; CI 95%: 583.31-943.16, p < 0.001) and the time sitting during the week decreased (-28.85 min/day; CI 95%: -43.94 to -13.77, p < 0.001). Also, eating habits improved in PREDIMED (2.58 units; CI 95%: 1.43-3.73, p < 0.001), decreased body weight (-0.88 kg; CI 95%: -1.26 to -0.49, p < 0.001), the abdominal perimeter (1.57 cm; CI 95%: 2.23-0.90, p < 0.001) and adipose tissue (-0.80%; CI 95%: -1.10 to -0.51, p < 0.001). CONCLUSIONS: An interdisciplinary program with high intensity variable continuous training combined with dynamic muscle toning increases functional capacity, the level of physical activity, improves body composition and eating habits in ACS patients.


Assuntos
Síndrome Coronariana Aguda , Treinamento Resistido , Síndrome Coronariana Aguda/terapia , Exercício Físico/fisiologia , Teste de Esforço , Humanos , Treinamento Resistido/métodos , Teste de Caminhada
2.
Acta Physiol (Oxf) ; 222(1)2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28371478

RESUMO

The transcriptional regulation of voltage-gated Ca2+ (CaV ) channels is an emerging research area that promises to improve our understanding of how many relevant physiological events are shaped in the central nervous system, the skeletal muscle and other tissues. Interestingly, a picture of how transcription of CaV channel subunit genes is controlled is evolving with the identification of the promoter regions required for tissue-specific expression and the identification of transcription factors that control their expression. These promoters share several characteristics that include multiple transcriptional start sites, lack of a TATA box and the presence of elements conferring tissue-selective expression. Likewise, changes in CaV channel expression occur throughout development, following ischaemia, seizures or chronic drug administration. This review focuses on insights achieved regarding the control of CaV channel gene expression. To further understand the complexities of expression and to increase the possibilities of detecting CaV channel alterations causing human disease, a deeper knowledge on the structure of the 5' upstream regions of the genes encoding these remarkable proteins will be necessary.


Assuntos
Canais de Cálcio/biossíntese , Regulação da Expressão Gênica/fisiologia , Animais , Canais de Cálcio/genética , Humanos
3.
Autoimmun Rev ; 14(7): 594-600, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25712147

RESUMO

P-glycoprotein (Pgp) is a transmembrane protein of 170 kD encoded by the multidrug resistance 1 (MDR-1) gene, localized on chromosome 7. More than 50 polymorphisms of the MDR-1 gene have been described; a subset of these has been shown to play a pathophysiological role in the development of inflammatory bowel disease, femoral head osteonecrosis induced by steroids, lung cancer and renal epithelial tumors. Polymorphisms that have a protective effect on the development of conditions such as Parkinson disease have also been identified. P-glycoprotein belongs to the adenosine triphosphate binding cassette transporter superfamily and its structure comprises a chain of approximately 1280 aminoacid residues with an N-C terminal structure, arranged as 2 homologous halves, each of which has 6 transmembrane segments, with a total of 12 segments with 2 cytoplasmic nucleotide binding domains. Many cytokines like interleukin 2 and tumor necrosis factor alpha increase Pgp expression and activity. Pgp functions as an efflux pump for a variety of toxins in order to protect particular organs and tissues as the central nervous system. Pgp transports a variety of substrates including glucocorticoids while other drugs such as tacrolimus and cyclosporine A act as modulators of this protein. The most widely used method to measure Pgp activity is flow cytometry using naturally fluorescent substrates such as anthracyclines or rhodamine 123. The study of drug resistance and its association to Pgp began with the study of resistance to chemotherapy in the treatment of cancer and antiretroviral therapy for human immunodeficiency virus; however, the role of Pgp in the treatment of systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis has been a focus of study lately and has emerged as an important mechanism by which treatment failure occurs. The present review analyzes the role of Pgp in these autoimmune diseases.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/imunologia , Doenças Autoimunes/imunologia , Doenças Reumáticas/imunologia , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Animais , Humanos , Polimorfismo Genético , Especificidade por Substrato
4.
Mol Biol Rep ; 42(2): 479-88, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25307018

RESUMO

Myotonic dystrophy type 1 (DM1) is a multisystem genetic disorder caused by a triplet nucleotide repeat expansion in the 3' untranslated region of the Dystrophia Myotonica-Protein Kinase (DMPK) gene. DMPK gene transcripts containing CUG expanded repeats accumulate in nuclear foci and ultimately cause altered splicing/gene expression of numerous secondary genes. The study of primary cell cultures derived from patients with DM1 has allowed the identification and further characterization of molecular mechanisms underlying the pathology in the natural context of the disease. In this study we show for the first time impaired nuclear structure in fibroblasts of DM1 patients. DM1-derived fibroblasts exhibited altered localization of the nuclear envelope (NE) proteins emerin and lamins A/C and B1 with concomitant increased size and altered shape of nuclei. Abnormal NE organization is more common in DM1 fibroblasts containing abundant nuclear foci, implying expression of the expanded RNA as determinant of nuclear defects. That transient expression of the DMPK 3' UTR containing 960 CTG but not with the 3' UTR lacking CTG repeats is sufficient to generate NE disruption in normal fibroblasts confirms the direct impact of mutant RNA on NE architecture. We also evidence nucleoli distortion in DM1 fibroblasts by immunostaining of the nucleolar protein fibrillarin, implying a broader effect of the mutant RNA on nuclear structure. In summary, these findings reveal that NE disruption, a hallmark of laminopathy disorders, is a novel characteristic of DM1.


Assuntos
Núcleo Celular/patologia , Fibroblastos/metabolismo , Fibroblastos/patologia , Distrofia Miotônica/genética , Distrofia Miotônica/patologia , Nucléolo Celular/patologia , Células Cultivadas , Humanos , Expansão das Repetições de Trinucleotídeos
5.
Transplant Proc ; 42(1): 353-6, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20172348

RESUMO

Enteric-coated tablets containing mycophenolate sodium have been developed to reduce gastric toxicity. The objective of this study was to compare 2 enteric-coated formulations containing 360 mg of mycophenolate sodium: the innovator product, Myfortic, and an agent that recently became available in Mexico, Femulan. For both formulations, mycophenolate sodium content was within the 90% to 110% range of the label claimed dose, and no impurities were present as determined at high-performance liquid chromatography. Mycophenolate sodium release was assayed by applying the US Pharmacopeia apparatus 2 dissolution test at 2 different pH values (1.2 and 6.8) to mimic conditions in the stomach and the small intestine, respectively. At pH 1.2, mycophenolate sodium release was less than 2%, with respect to the label claimed dose, for both formulations. At pH 6.8, mean (range) mycophenolate sodium release with Myfortic was 104.9% (104.0%-105.6%), and with femulan was 62.3% (51.3%-67.7%); the difference between formulations achieved statistical significance (P = .04). Moreover, intratablet variability with the generic formulation was unacceptable. Variation between the highest and lowest drug release was 32.0% for Femulan, and 1.02% for Myfortic. Thus, it is likely that Femulan results in insufficient and irreproducible absorption of mycophenolate sodium in the small intestine, leading to inadequate immunosuppressive efficacy. It is concluded that Femulan and myfortic are not equivalent formulations. Furthermore, Femulan is not a suitable formulation for clinical use in organ transplantation because it does not meet pharmaceutical quality standards.


Assuntos
Imunossupressores/química , Ácido Micofenólico/química , Ácido Micofenólico/farmacocinética , Comprimidos com Revestimento Entérico , Estabilidade de Medicamentos , Medicamentos Genéricos/química , Concentração de Íons de Hidrogênio , México , Ácido Micofenólico/uso terapêutico , Sódio , Solubilidade , Soluções
6.
J Cell Biochem ; 105(3): 735-45, 2008 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-18680104

RESUMO

Dystrophin and dystrophin-associated proteins (DAPs) form a complex around the sarcolemma, which gives stability to the sarcolemma and leads signal transduction. Recently, the nuclear presence of dystrophin Dp71 and DAPs has been revealed in different non-muscle cell types, opening the possibility that these proteins could also be present in the nucleus of muscle cells. In this study, we analyzed by Immunofluorescence assays and Immunoblotting analysis of cell fractions the subcellular localization of Dp71 and DAPs in the C(2)C(12) muscle cell line. We demonstrated the presence of Dp71, alpha-sarcoglycan, alpha-dystrobrevin, beta-dystroglycan and alpha-syntrophin not only in plasma membrane but also in the nucleus of muscle cells. In addition, we found by Immunoprecipitation assays that these proteins form a nuclear complex. Interestingly, myogenesis modulates the presence and/or relative abundance of DAPs in the plasma membrane and nucleus as well as the composition of the nuclear complex. Finally, we demonstrated the presence of Dp71, alpha-sarcoglycan, beta-dystroglycan, alpha-dystrobrevin and alpha-syntrophin in the C(2)C(12) nuclear envelope fraction. Interestingly, alpha-sarcoglycan and beta-dystroglycan proteins showed enrichment in the nuclear envelope, compared with the nuclear fraction, suggesting that they could function as inner nuclear membrane proteins underlying the secondary association of Dp71 and the remaining DAPs to the nuclear envelope. Nuclear envelope localization of Dp71 and DAPs might be involved in the nuclear envelope-associated functions, such as nuclear structure and modulation of nuclear processes.


Assuntos
Núcleo Celular/metabolismo , Proteínas Associadas à Distrofina/análise , Distrofina/análise , Células Musculares/metabolismo , Desenvolvimento Muscular/fisiologia , Membrana Nuclear/metabolismo , Animais , Membrana Celular/metabolismo , Células Cultivadas , Distrofina/genética , Distrofina/metabolismo , Complexo de Proteínas Associadas Distrofina/análise , Complexo de Proteínas Associadas Distrofina/metabolismo , Proteínas Associadas à Distrofina/genética , Proteínas Associadas à Distrofina/metabolismo , Imunofluorescência , Camundongos , RNA Mensageiro/metabolismo
7.
Soc Biol ; 40(3-4): 161-90, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8178186

RESUMO

Mexico has a large and rapidly growing labor force. This paper projects the Mexican national labor force from 1980 to 2005, with varying assumptions of vital rates, economic activity, and international migration. Projections are also made for the urban and rural components of the Mexican population, assuming inter-component migration flows. Results indicate that the Mexican labor force will grow over the projection period at an average annual rate of 907,000 to 1,183,000 workers; will age slightly; and will have a much higher proportion female. Implications are discussed in terms of Mexican-U.S. migration, possible agreements on free trade, and global trends in workforce.


Assuntos
Emprego/estatística & dados numéricos , Adulto , Fatores Etários , Emigração e Imigração/estatística & dados numéricos , Feminino , Fertilidade , Previsões , Humanos , Masculino , México , Pessoa de Meia-Idade , Dinâmica Populacional , Fatores Sexuais , Fatores Socioeconômicos , Mulheres Trabalhadoras/estatística & dados numéricos
8.
Rev. méd. IMSS ; 19(1): 33-7, 1981.
Artigo em Espanhol | LILACS | ID: lil-11152

RESUMO

Se presenta el caso de un adolescente con hipertension arterial grave, en quien clinicamente y por metodos de gabinete se considero que la hipertension era de origen renovascular. La arteriografia renal mostro compresion de la arteria renal derecha por un tumor parapielico. El estudio histologico del mismo revelo que se trataba de un feocromocitoma extraadrenal. El paciente se curo de la hipertension arterial despues de la nefrectomia y extirpacion del tumor


Assuntos
Adolescente , Humanos , Masculino , Feocromocitoma , Neoplasias das Glândulas Suprarrenais , Hipertensão , Artéria Renal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...